InflaRx Receives Nasdaq Notice for Minimum Bid Price Non-Compliance, Awaits Compliance Deadline

InflaRx has received a notice from Nasdaq that its share price has consistently fallen below the minimum of $1.00 required for continued listing. The company has 180 days to regain compliance, and may apply to move its listing to the Nasdaq Capital Market if needed. InflaRx is developing several treatments for inflammatory diseases, including Izicopan and Vilobelimab, which has EU approval for COVID-19 treatment. The company plans to discuss a potential development path with the FDA for Vilobelimab in ulcerative pyoderma gangrenosum and will report full-year 2025 results in March 2026.